A Protective Role of Glibenclamide in Inflammation-Associated Injury.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
hypoglycemia 2 endocrinologydiseases
type 2 diabetes mellitus 1 endocrinologydiseases
cyclophosphamide 3 endocrinologydiseasesdrugs
diabetes mellitus 2 endocrinologydiseases
glipizide 1 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
cyclophosphamide 8510 problem in urology. Hughes et al. indicated that NLRP3 played an important role in the pathogenesis of cyclophosphamide -induced cystitis, while glibenclamide could effectively block the inflammatory response [[16]]. In a
cyclophosphamide 8628 cyclophosphamide-induced cystitis, while glibenclamide could effectively block the inflammatory response [[16]]. In a cyclophosphamide -induced rat model of cystitis, glibenclamide treatment decreased caspase-1 activity along with levels
cyclophosphamide 23487 cerulean-induced obese mouse model of SAP, or in an adenine-diet rat model of chronic kidney disease, or in a cyclophosphamide -induced rat model of bladder inflammation, or in a lipopolysaccharide-induced myocardial injury in streptozocin-induced
glipizide 24241 for inhibition of the NLRP3 inflammasome [[58]]. As evidence showed that another sulfonylurea drug glipizide also inhibited Sur1 containing KATP channels but failed to inhibit NLRP3 inflammasome activation. Glibenclamide
Select Disease Character Offset Disease Term Instance
diabetes mellitus 583 (epub): 6/2017AbstractGlibenclamide is the most widely used sulfonylurea drug for the treatment of type 2 diabetes mellitus (DM). Recent studies have suggested that glibenclamide reduced adverse neuroinflammation and improved
diabetes mellitus 1723 sulfonamides caused hypoglycemia in animals. Thereafter, glibenclamide has been used widely in the type II diabetes mellitus (DM).The mechanism of glibenclamide in DM treatment is due to its inhibition of ATP-sensitive potassium
hypoglycemia 1636 [[1]]. Actually, sulfonylureas were discovered accidentally, as the antimicrobial sulfonamides caused hypoglycemia in animals. Thereafter, glibenclamide has been used widely in the type II diabetes mellitus (DM).The
hypoglycemia 3394 combination of Kir6.2 and Sur2B (Sur2B-Kir6.2)4; or Kir6.1 and Sur2B (Sur2B-Kir6.1)4 [[5]].Besides its hypoglycemia effects, glibenclamide recently has been shown to play role in inflammation regulation. In addition
type 2 diabetes mellitus 576 (epub): 6/2017AbstractGlibenclamide is the most widely used sulfonylurea drug for the treatment of type 2 diabetes mellitus (DM). Recent studies have suggested that glibenclamide reduced adverse neuroinflammation and improved

You must be authorized to submit a review.